You might also like
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and clinical testing of small molecule therapeutics. The company targets deregulated transcription, a hallmark of cancer and other serious diseases, including autoimmune disorders. Kronos Bio operates in one business segment, which is the development of biopharmaceutical products.
- Collaboration with Genentech - Engages in strategic collaborations to generate revenue through upfront payments recognized over the term of the estimated period of performance.
- Research and Development - Develops therapeutics addressing deregulated transcription, conducting preclinical and clinical trials for product candidates.
- Manufacturing and Supply Chain - Relies on third-party manufacturers for the production of active pharmaceutical ingredients and other supplies needed for testing.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Sandra Gardiner Executive | interim Chief Financial Officer | Board Director at Levitas Bio; Board Chair at Valley Humane Society | Sandra Gardiner is the interim Chief Financial Officer and principal financial officer and accounting officer at KRON since September 2023. She brings extensive financial leadership experience from previous roles, including CFO at Pulse Biosciences, Inc.. | |
Norbert Bischofberger Board | Member of the Board of Directors | Member of the Board at Vir Biotechnology, Inc. | Norbert Bischofberger, Ph.D., served as President and CEO of Kronos Bio from April 2018 until December 2024 and has been a member of the Board of Directors since April 2018. He brings extensive experience in life sciences research and executive leadership, making key contributions in the biopharmaceutical industry. | |
Christopher Dinsmore | Strategic Advisor | Christopher Dinsmore, Ph.D. served as the Chief Scientific Officer at KRON from June 15, 2020 until his employment was terminated on January 24, 2024. He continues to contribute to the company as a strategic advisor. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
CellCentric | Developing a p300/CBP Bromodomain inhibitor, inobrodib, which is in Phase I/II clinical development as a potential competitor to KB-9558 if approved. |
Pathos | Developing FT-7051, a p300/CBP BRD inhibitor, which is in early-stage clinical development and could compete with KB-9558 if approved. |
Epigenetix | Developing EP31670, a p300/CBP BRD inhibitor, which is in early-stage clinical development and could compete with KB-9558 if approved. |
Tolremo | Developing TT125-802, a p300/CBP BRD inhibitor, which is in early-stage clinical development and could compete with KB-9558 if approved. |
Aurigene | Developing AUR-107, a p300/CBP BRD inhibitor, which is in early-stage clinical development and could compete with KB-9558 if approved. |
Developing ianalumab (VAY736), a BAFF-R Mab, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Developing deucravacitinib (SOTKTU), a TYK2 inhibitor, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Developing dazodalibep (VIB4920), a CD40L antagonist, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
RemeGen | Developing telitacicept, a BlyS and April neutralizer, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. |
Developing bariicibinib (OLUMIANT), a JAK 1/2 inhibitor, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Developing nipocalimab, an anti-FcRn inhibitor, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Developing anifrolumab, an anti-IFNalpha mAb, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Developing efgartigimod, an anti-FcRn inhibitor, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. | |
Astellas | Developing ASP45502, a STING inhibitor, which is in clinical development for Sjogren's Syndrome and could compete with KB-7898 if approved. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Genentech | Collaboration and License Agreement | All | $9.8 million of revenue in 2024 (representing 100% of Kronos Bio’s total revenue) , and $6.3 million of revenue in 2023 (also 100% of total revenue). |
Recent press releases and 8-K filings for KRON.
- Kronos Bio will be acquired by Concentra Biosciences for $0.57 in cash per share plus one contingent value right, providing potential future payments tied to product candidate dispositions.
- The acquisition is approved by the Kronos Bio Board, with a tender offer scheduled to commence by May 15, 2025, subject to customary closing conditions, including securing at least $40.0 million in cash.
- Kronos Bio, Inc. reported its Q4 2024 financial results on March 18, 2025, with a net loss of $25.8 million and a full-year net loss of $86.1 million, corresponding to $0.43 and $1.43 per share respectively.
- The company recorded cash, cash equivalents, and investments of $112.4 million as of December 31, 2024, and provided detailed breakdowns of R&D, G&A, and impairment charges in the quarter and full year.
- The press release also highlighted significant non-cash expenses, including stock-based compensation and restructuring charges, underscoring the company’s rigorous expense management during fiscal 2024.